These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31686231)

  • 1. The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus.
    Veilleux A; Di Marzo V; Silvestri C
    Curr Diab Rep; 2019 Nov; 19(11):117. PubMed ID: 31686231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the Endocannabinoidome in Human and Mouse Atherosclerosis.
    Piscitelli F; Silvestri C
    Curr Pharm Des; 2019; 25(29):3147-3164. PubMed ID: 31448709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and Concomitant Gut Microbiota and Endocannabinoidome Response to Diet-Induced Obesity in Mice.
    Lacroix S; Pechereau F; Leblanc N; Boubertakh B; Houde A; Martin C; Flamand N; Silvestri C; Raymond F; Di Marzo V; Veilleux A
    mSystems; 2019 Dec; 4(6):. PubMed ID: 31848310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
.
    Di Marzo V
    Dialogues Clin Neurosci; 2020 Sep; 22(3):259-269. PubMed ID: 33162769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurobiological Processes Induced by Aerobic Exercise through the Endocannabinoidome.
    Forteza F; Giorgini G; Raymond F
    Cells; 2021 Apr; 10(4):. PubMed ID: 33920695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulatory role of the endocannabinoidome in the pathophysiology of the gastrointestinal tract.
    Lian J; Casari I; Falasca M
    Pharmacol Res; 2022 Jan; 175():106025. PubMed ID: 34883211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling.
    Manca C; Boubertakh B; Leblanc N; Deschênes T; Lacroix S; Martin C; Houde A; Veilleux A; Flamand N; Muccioli GG; Raymond F; Cani PD; Di Marzo V; Silvestri C
    J Lipid Res; 2020 Jan; 61(1):70-85. PubMed ID: 31690638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Endocannabinoid System and its Modulation by Phytocannabinoids.
    Di Marzo V; Piscitelli F
    Neurotherapeutics; 2015 Oct; 12(4):692-8. PubMed ID: 26271952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endocannabinoid system and its therapeutic exploitation.
    Di Marzo V; Bifulco M; De Petrocellis L
    Nat Rev Drug Discov; 2004 Sep; 3(9):771-84. PubMed ID: 15340387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of brain endocannabinoidome signaling in germ-free mice.
    Manca C; Shen M; Boubertakh B; Martin C; Flamand N; Silvestri C; Di Marzo V
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Dec; 1865(12):158786. PubMed ID: 32795503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes.
    Di Marzo V; Piscitelli F; Mechoulam R
    Handb Exp Pharmacol; 2011; (203):75-104. PubMed ID: 21484568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Missing Pieces to the Endocannabinoid Puzzle.
    Maccarrone M
    Trends Mol Med; 2020 Mar; 26(3):263-272. PubMed ID: 31822395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocannabinoid regulation of β-cell functions: implications for glycaemic control and diabetes.
    Jourdan T; Godlewski G; Kunos G
    Diabetes Obes Metab; 2016 Jun; 18(6):549-57. PubMed ID: 26880114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome.
    Di Marzo V; Silvestri C
    Nutrients; 2019 Aug; 11(8):. PubMed ID: 31434293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The endocannabinoid system: an osteopathic perspective.
    McPartland JM
    J Am Osteopath Assoc; 2008 Oct; 108(10):586-600. PubMed ID: 18948642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoids and the gut: new developments and emerging concepts.
    Izzo AA; Sharkey KA
    Pharmacol Ther; 2010 Apr; 126(1):21-38. PubMed ID: 20117132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders.
    Sihag J; Di Marzo V
    Lipids Health Dis; 2022 Jan; 21(1):9. PubMed ID: 35027074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of the endocannabinoid system in the brain.
    Ramos JA; González S; Sagredo O; Gómez-Ruiz M; Fernández-Ruiz J
    Mini Rev Med Chem; 2005 Jul; 5(7):609-17. PubMed ID: 16026307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocannabinoid Signalling in Atherosclerosis and Related Metabolic Complications.
    Guillamat-Prats R; Rami M; Herzig S; Steffens S
    Thromb Haemost; 2019 Apr; 119(4):567-575. PubMed ID: 30769363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.
    Vemuri VK; Janero DR; Makriyannis A
    Physiol Behav; 2008 Mar; 93(4-5):671-86. PubMed ID: 18155257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.